Navigation Links
Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
Date:8/24/2009

SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that its Board of Directors has elected Paulo F. Costa as Chairman of the Board, effective immediately.

Mr. Costa was formerly President and Chief Executive Officer of Novartis U.S. Corporation, where he held several other executive positions, including Head of the Americas and President and Chief Executive Officer of Novartis Pharmaceutical Corporation. Prior to joining Novartis, Mr. Costa worked at Johnson & Johnson for 30 years, where he served as President of Janssen Pharmaceutica, Executive Vice President, Global Franchise Development, and was a member of Johnson & Johnson's Group Operating Committee. Mr. Costa has held various sales and marketing positions and has more than 20 years of general management experience, having launched 10 pharmaceutical products in various therapeutic areas in the U.S. market. He was elected to Amylin's Board at the Company's Annual Meeting of Stockholders on May 27, 2009.

"Our unanimous decision to name Paulo as Chairman reflects the Board's confidence in his leadership abilities," said James R. Gavin III, M.D., Ph.D., Director and Chair of Amylin's Corporate Governance Committee. "Paulo brings a fresh perspective to all aspects of Amylin's business at this important time for the Company, and his expertise regarding operational and commercial activities will be invaluable as we prepare for the launch of exenatide once weekly. We continue to position Amylin to compete and win in the diabetes and obesity markets. On behalf of the entire Board of Directors, we look forward to working with Paulo in his new leadership role."

"It is with great honor and pleasure that I accept the position of Amylin's Chairman," said Mr. Costa. "I am excited about working closely with my fellow Directors to help Amylin successfully discover, develop and commercialize innovative medicines to improve the lives of patients with diabetes. By doing this well, we will deliver superior value to our shareholders."

Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed due to a number of risks and uncertainties, including that our clinical trials may not start when planned and/or confirm previous results; our preclinical studies may not be predictive; our product candidates may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, including its Form 10-Q. Amylin undertakes no duty to update these forward-looking statements.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals to Webcast Second Quarter Results
2. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
3. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
4. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
5. Amylin Announces Preliminary Tabulation of Annual Meeting Results
6. Amylin Responds to Eastbourne Letter
7. Amylin Comments on RiskMetrics Report
8. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
9. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
10. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
11. Amylin Issues Statement in Response to Carl Icahn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... essential device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 ... E FPGA into a compact business-card sized form factor suitable for prototyping, testing, ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... for Clinical Ops Executives 2017 in its continued commitment to the advancement of ... makers to discuss current issues related to clinical trial planning and management. ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... Researchers from a new study ... not fall low enough after prostate cancer treatment, this indicates there is still remaining prostate ... of mortality. , “ The PSA test has always been an indicator of whether a ...
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 ... launched an investigation into whether the board members of ... their fiduciary duties in connection with the proposed sale ... is a biopharmaceutical company that develops small molecules for ... 18, 2017, CoLucid announced it had signed a definitive ...
Breaking Biology Technology:
(Date:12/15/2016)... Germany , December 15, 2016 ... today announced an agreement with NuData Security, an award-winning ... The partnership will enable clients to focus on good customer ... data protection regulation. ... In order to provide a one-stop fraud prevention ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much more ... or starting the engine. Continental will demonstrate the intelligence ... Las Vegas . Through the combination of the ... Entry) and biometric elements, the international technology company is ... personalization and authentication. "The integration of biometric ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):